Sanofi Aventis
Subscribe to Sanofi Aventis

The Lead

FDA panel backs first-in-class cholesterol drug

June 10, 2015 11:55 am | by Matthew Perrone, AP Health Writer | News | Comments

Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce heart attacks.

Innate Pharma and Sanofi Collaboration

April 16, 2015 11:28 am | by Innate Pharma SA | News | Comments

Innate Pharma SA has entered into a collaboration with Sanofi to apply site-specific conjugation...

Studies Boost Hopes for New Class of Cholesterol Medicines

March 16, 2015 8:02 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can...

Ex-Sanofi CEO Joins PureTech's Board of Directors

February 27, 2015 8:09 am | News | Comments

PureTech, a science and technology R&D company focused  on identifying, inventing and...

View Sample

FREE Email Newsletter

Sanofi Hires Bayer HealthCare's Brandicourt as New CEO

February 20, 2015 8:12 am | News | Comments

Sanofi said Thursday Brandicourt, 59, will start on April 2. He has been Bayer HealthCare's chairman and CEO since November 2013, and was also an executive for Pfizer Inc.

Sanofi Announces Massachusetts Layoffs

February 11, 2015 3:52 pm | by Andrew Szal, Editor, Pharmaceutical Processing | News | Comments

Sanofi SA acknowledged the job cuts in its Genzyme division Wednesday. The layoffs will largely effect facilities in Cambridge, with about 70 at the rare disease-focused Sanofi Genzyme Research and Development Center and 30 at a smaller cancer research center.

Boehringer Ingelheim and Sanofi to Collaborate on Manufacturing Biopharmaceuticals

January 15, 2015 8:34 am | News | Comments

Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.              


Catalent and Sanofi to Collaborate On Smartag™ Antibody-Drug Conjugate Technology With Sanofi’s Proprietary Antibodies

January 15, 2015 8:07 am | News | Comments

Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates (ADCs).

Paralegal Says Sanofi Fired Her for Whistleblowing

December 8, 2014 8:41 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

A paralegal recently fired by French drugmaker Sanofi has filed a whistleblower lawsuit, claiming she was discharged after protesting an alleged kickback scheme to increase U.S. sales of its insulin medicines.       

FDA Approves Priftin Tablets for the Treatment of Latent Tuberculosis Infection

December 2, 2014 9:08 am | News | Comments

Sanofi announced today that following a priority review, the FDA has approved Priftin in combination with isoniazid for a new indication for the treatment of latent tuberculosis infection in patients two years of age and older at high risk of progression to tuberculosis disease.

Sanofi Ousts CEO Amid Pressure Over Diabetes Drug

October 29, 2014 8:08 am | by GREG KELLER, Associated Press | News | Comments

Sanofi sacked its CEO Wednesday following a board room rift over the handling of one of France's largest publicly traded companies. Christopher Viehbacher, the first non-Frenchman to lead Sanofi, was dismissed after six years running the company that traces its roots to the early 19th century.

Sanofi Shares Plunge Due to Diabetes Drug Pricing Pressures

October 28, 2014 8:20 am | News | Comments

Sanofi saw its stock price plunge today after it reported a slide in quarterly earnings and warned of pricing pressure on its blockbuster diabetes treatment in the U.S. Sanofi shares fell 8.4 percent to 76.39 euros, forfeiting gains in the run-up to the announcement.


Shortage of Bladder Cancer Drug Could be Tragic for Patients, Doctor Says

September 9, 2014 8:32 am | by Sheryl Ubelacker, The Canadian Press | News | Comments

The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.        

Trial: Dengue Shot Offers Some Protection

July 11, 2014 8:19 am | by MARIA CHENG, AP Medical Writer | News | Comments

The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial.       

Analyst: Sanofi Facing Triple Threat from Eli Lilly for Diabetes Treatment Market Space

June 25, 2014 8:13 am | News | Comments

The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market, and the US-based company has three big weapons in its pharmaceutical arsenal, says an analyst with research and consulting firm GlobalData.

Sanofi and Lilly Announce Licensing Agreement for Cialis OTC

May 28, 2014 8:39 am | News | Comments

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

Meningococcal Vaccine Market Expected To Hit $3.76B By 2019

May 9, 2014 9:34 am | News | Comments

According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.


Former Pharma Exec Gets 16 Months in Inside-Trader Case

April 22, 2014 2:37 pm | News | Comments

A former pharmaceutical executive has been sentenced to 16 months in prison for his role in an insider trading scheme. John Lazorchak was sentenced Tuesday in federal court in Newark, N.J.           

Aastrom to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business

April 21, 2014 8:41 am | News | Comments

Aastrom Biosciences announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million.                       

Former NJ Drug Execs Sentenced in Stock Scheme

April 17, 2014 8:12 am | News | Comments

Two former pharmaceutical and medical technology firm executives have been sentenced for their involvement in an insider trading scheme.                   

Sanofi Earnings Soar on Lower Restructuring Costs

February 6, 2014 7:55 am | News | Comments

Sanofi said today its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments.               

Sanofi Says Insulin U300 Met Study Goals

December 4, 2013 8:11 am | News | Comments

Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials, but some results were mixed.  U300 is intended to be a longer-lasting version of Lantus that can be administered in lower doses. The company plans to file for marketing approval in the U.S. and European Union in the first half of 2014.

Sanofi Profit Slumped 21% in Q3

October 30, 2013 7:59 am | News | Comments

Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring. Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.

Former NJ Drug Execs, Admit Roles in Stock Scheme

October 9, 2013 8:24 am | News | Comments

John Lazorchak, a former director of financial reporting at Summit-based Celgene Corp., and Mark Cupo, who held a similar position at Sanofi-Aventis, a France-based company with U.S. headquarters in Bridgewater, each pleaded guilty in federal court Monday to five counts of securities fraud.

Sanofi Re-Introduces Rolaids in the United States

September 16, 2013 8:16 am | News | Comments

Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.

Group: China Targets Foreign Companies in Probes

September 5, 2013 8:33 am | News | Comments

The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.

Sanofi to Sell Pozen Cardiovascular Drugs in US

September 4, 2013 5:08 pm | by The Associated Press | News | Comments

Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies...

Pending Research to Offer Clues for Possible H7N9 Vaccine

August 19, 2013 9:34 am | by Helen Branswell, The Canadian Press | News | Comments

Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.

China Probes Sanofi for Alleged Bribery

August 12, 2013 8:12 am | News | Comments

Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.